ArticleThe Lancet. Rheumatology2022

Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial.

Jagdeep Nanchahal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.